John Moroney, MD

  • Associate Professor of Obstetrics and Gynecology
    Associate Professor of Medicine
  • Clinical Interests: Abnormal Placentation, Cervical Cancer, Clinical Trials, Complex DaVinci robot-assisted minimally invasive surgical techniques, Fertility preserving surgical techniques for cervical uterine and ovarian cancers, Gynecologic Cancers, Investigational (Phase I/II) drug development and early clinical trials, Ovarian Cancer, Surgical and medical care of obstetric patients with cancer, Uterine Cancer
  • Websites: Research Network Profile
  • Contact: jwmoroney@bsd.uchicago.edu

John Moroney, MD, specializes in the diagnosis and treatment of gynecologic cancers, with a focus on providing skilled and personalized longitudinal care. He believes that access to innovative surgical techniques and targeted medical therapies are essential in achieving optimal outcomes.



Dr. Moroney is the principal investigator (PI) at the University of Chicago for NRG Oncology, a National Cancer Institute-supported clinical trials cooperative group. He also serves as the PI for numerous other industry-sponsored clinical trials.

Loyola University Stritch School of Medicine
MD

Walter Reed National Military Medical Center
Internship

Walter Reed National Military Medical Center
Residency

MD Anderson Cancer Center
Fellowship

Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer.
Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer. Gynecol Oncol. 2025 May 19; 198:1-8.
PMID: 40393272

Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor a-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial.
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor a-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol. 2025 Apr; 26(4):503-515.
PMID: 40179908

An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044).
An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044). Gynecol Oncol. 2025 Mar; 194:145-152.
PMID: 40221173

NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024.
NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024 10; 22(8):512-519.
PMID: 39413835

NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer.
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer. 2024 Apr 15; 130(8):1234-1245.
PMID: 38127487

Mirvetuximab Soravtansine in FRa-Positive, Platinum-Resistant Ovarian Cancer.
Mirvetuximab Soravtansine in FRa-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med. 2023 12 07; 389(23):2162-2174.
PMID: 38055253

A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283. Gynecol Oncol. 2023 09; 176:16-24.
PMID: 37418832

Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer.
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer. JAMA Oncol. 2022 09 01; 8(9):1317-1322.
PMID: 35900726

Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer.
Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer. J Clin Invest. 2022 07 15; 132(14).
PMID: 35671108

A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study.
A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study. Gynecol Oncol. 2022 03; 164(3):481-491.
PMID: 35063278

View All Publications